Your browser doesn't support javascript.
loading
Genetic modifiers of multiple sclerosis progression, severity and onset.
Sadovnick, A Dessa; Traboulsee, Anthony L; Zhao, Yinshan; Bernales, Cecily Q; Encarnacion, Mary; Ross, Jay P; Yee, Irene M; Criscuoli, Maria G; Vilariño-Güell, Carles.
Afiliación
  • Sadovnick AD; Department of Medical Genetics, University of British Columbia, Vancouver, Canada; Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Traboulsee AL; Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Zhao Y; Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Bernales CQ; Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
  • Encarnacion M; Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
  • Ross JP; Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
  • Yee IM; Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
  • Criscuoli MG; Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
  • Vilariño-Güell C; Department of Medical Genetics, University of British Columbia, Vancouver, Canada. Electronic address: carles@can.ubc.ca.
Clin Immunol ; 180: 100-105, 2017 07.
Article en En | MEDLINE | ID: mdl-28501589
ABSTRACT
The genetic contribution to clinical outcomes for multiple sclerosis (MS) has yet to be defined. We performed exome sequencing analysis in 100 MS patients presenting opposite extremes of clinical phenotype (discovery cohort), and genotyped variants of interest in 2016 MS patients (replication cohort). Linear and logistic regression analyses were used to identify significant associations with disease course, severity and onset. Our analysis of the discovery cohort nominated 38 variants in 21 genes. Replication analysis identified PSMG4 p.W99R and NLRP5 p.M459I to be associated with disease severity (p=0.002 and 0.008). CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p=0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p=0.031 and 0.023). In addition, PSMG4 p.W99R and NLRP5 p.R761L were found to correlate with an earlier age at MS clinical onset, and MC1R p.R160W with delayed onset of clinical symptoms (p=0.010-0.041).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Autoantígenos / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Autoantígenos / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Canadá